Filing Flows › Sutro Biopharma (STRO) › Q4 2024
Sutro Biopharma (STRO) Q4 2024 earnings results (fourth quarter 2024)
10-K filed Mar 13, 2025
Sutro Biopharma (STRO) reported revenue of $14.8M for the fourth quarter 2024 (Q4 2024), -87% from a year earlier and +74% from the quarter before. Operating margin was -440.7%, net loss $72.4M (489.2% of revenue).
Sutro Biopharma, Q4 2024: revenue $14.8M (-87% year over year), operating margin -440.7%, net loss $72.4M, operating cash flow −$71.7M. The chart follows the revenue to costs, profit and cash.
| Q4 2024 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $14.8M | +74% | -87% |
| Operating profit | −$65.3M | — | — |
| Net earnings | −$72.4M | — | — |
| Operating cash flow | −$71.7M | — | — |
What changed
Revenue was $14.8M in Q4 2024, down 87% year over year and up 74% from the previous quarter.
Operating costs exceeded revenue by $65.3M, an operating margin of -440.7%. Total costs grew 13% against a revenue fall of 87%. The fastest-growing cost line was Research & development (+32%). The quarter ended with a net loss of $72.4M, wider than the previous quarter's $48.8M loss.
Operating cash flow was −$71.7M. Non-cash charges added back $1.9M of depreciation and amortization and $5.9M of share-based compensation. Working capital and other items used $7.1M.
Questions
What was Sutro Biopharma's revenue in the fourth quarter 2024?
Sutro Biopharma (STRO) reported revenue of $14.8M for the fourth quarter 2024 (Q4 2024), -87% from a year earlier and +74% from the quarter before.
Was Sutro Biopharma profitable in the fourth quarter 2024?
Operating loss was $65.3M (-440.7% of revenue) and net loss $72.4M.
Source: Sutro Biopharma 10-K on SEC EDGAR.